Shuttle Pharmaceuticals Holdings, Inc. filed a Current Report on Form 8-K dated November 13, 2026, disclosing an amendment to its Securities Purchase Agreement. The amendment, entered into with investors representing at least 67% of the original purchasers, extends the deadlines for the registration of securities issued in a private placement that closed on May 6, 2026.

Under the amended agreement, the Company is required to file registration statements covering the resale of securities, with the SEC required to declare them effective by specific dates: January 31, 2027, for Conversion Shares and Warrant Shares; March 1, 2027, for one-third of Milestone Shares; April 1, 2027, for an additional one-third of Milestone Shares; and May 1, 2027, for the final one-third of Milestone Shares.

The filing also details the issuance of pre-funded warrants following the determination that Milestone Events had been satisfied. The Company issued Milestone Pre-Funded Warrants to three groups: purchasers under the Securities Purchase Agreement (up to 2,099,142 shares), former stockholders of United Dogecoin Inc. (up to 4,097,584 shares), and EF Hutton and one other recipient (up to 497,014 shares). These warrants have an exercise price of $0.001 per share and are exercisable immediately.

The Company reported that as of November 13, 2026, it had issued pre-funded warrants to purchase a total of 16,932,506 shares of common stock across all parties. These warrants were issued under the Securities Purchase Agreement and the Merger Agreement and rely on exemptions from registration under the Securities Act.